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to prevent the formation or progression of cataracts.
Objective: Understanding the protein changes during various stages of cataracts might help realize the
mechanism of the formation and progression of cataracts.
Methods: Lens materials were collected from cataract surgery. Cataracts were classiﬁed according to
lens opacity using the gradation of the Lens Opacities Classiﬁcation System. Lens proteins were
separated by 2-dimensional polyacrylamide gel electrophoresis. Protein spots were visualized by
Coomassie blue staining, and expression patterns were analyzed. Protein spots of interest were excised
from 2-dimensional polyacrylamide gel electrophoresis gels, digested in situ with trypsin, and analyzed
by mass spectrometry and liquid chromatographic tandem mass spectrometry.
Results: Crystallin was the major protein in the cataract lens, and aA, bB1, aB, and bA4 were the
dominant types. Crystallin aB and bA4 increased with the formation of lens opacity. Moreover,
phosphorylation and truncation of these proteins increased with the progression of cataracts.
Conclusion: Crystallin aB and bA4 and phosphorylation and truncation of crystallin in the lens might
contribute to the formation of cataracts. In contrast, acetylation was not dominant in the progression of
cataracts and did not play major role in the formation of cataracts.
& 2013. The Authors. Published by Elsevier Inc. Open access under CC BY license.Introduction
The effect of cataracts on vision is often described as being
similar to looking through a waterfall or a piece of waxed paper.
Poor vision from cataracts affects 80% of people aged Z75 years.1
This disease causes clouding of the eye lens, which reduces the
amount of incoming light and deteriorates vision. Daily functions
such as reading or driving a car may become difﬁcult or impossible.2
Thus, patients may require frequent change in eyeglass prescrip-
tions.3 It is estimated that 200 million people have cataractsier Inc.
hD, Department of Medical
ospital, No. 2 Yuh-Der Road,
).
k.
Open access under CC BY liceworldwide.4,5 Data from the National Institutes of Health indicate
that 4350,000 cataract surgeries are performed annually in the
United States.
The lens is the clear part of the eye that helps to focus light and
images on the retina.6 The retina is the light-sensitive tissue at the
back of the eye. In a normal eye, light passes through the
transparent lens to the retina. Once it reaches the retina, light is
changed into nerve signals that are sent to the brain.7 The lens
must be clear for the retina to receive a sharp image. If the lens is
cloudy as a result of cataracts, the image will be blurred. The lens
is mostly made of water and protein. The proteins are arranged to
let light pass through and focus on the retina. Sometimes, some
lens proteins clump together and begin to cloud a small area of
the lens. Over time, the cells accumulate and cause the lens to
cloud, thereby resulting in blurred or fuzzy images.4,8 Cataracts
are the leading cause of visual loss among adults 455 years old.
Cataract surgery costs Medicare more money than any other
medical procedure, with 60% of those who initially qualify for
Medicare already having cataracts.9 Most people are concerned
regarding the time of onset of cataracts and not about itsnse.
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lead to good eye health and prevent cataracts.10 Many factors
inﬂuence vision and cataract development, for example, age,
nutrition, heredity, medications, toxins, health habits, sunlight
exposure, and head trauma. Cataracts can also be caused by high
blood pressure, kidney disease, diabetes, or direct trauma to the
eye.11,12 Although cataract surgeries have advanced progressively,
cataracts are still the leading cause of blindness and are a
profound economic cost to society.13–15 In this study, we used
2-dimensional polyacrylamide gel electrophoresis (2D-PAGE) to
identify the proteins that change during the formation of lens
opacity and liquid chromatographic tandem mass spectrometry
(LC/MS/MS) to evaluate post-translation modiﬁcations of the
proteins. Investigating the protein changes during various stages
of cataracts elucidated the mechanism of the formation of
cataracts and might be helpful in designing new therapies.Materials and Methods
Lens materials were obtained during cataract surgery. All
patients in this study received serial ophthalmic examinations,
including intraocular pressure (IOP), visual acuity, and retinal
examination. Patients with ocular diseases other than cataracts
were excluded. Patients (38 women and 42 men), aged 56 to 85
years (mean, 72 years), were followed up after 3 to 24 weeks
(mean, 5 weeks). The study was performed according to the
tenets of the Declaration of Helsinki for research involving human
participants.
Patients with Stage 2 to 5 cataracts were enrolled in the study.
The patients did not have any systemic diseases or eye diseases
other than cataracts. They underwent phacoemulsiﬁcation sur-
gery using a phacoemulsiﬁcation machine (Universal II; Alcon,
Houston, Texas). Lens materials were collected into bags by the
machine after quaking the lens into small particles by ultrasound.
Lens opacity was classiﬁed according to the Lens Opacities
Classiﬁcation System (LOCS) before surgery.16,17 This classiﬁca-
tion involves comparison of the slit lamp view of the lens to a
color plate of LOCS III standards. LOCS uses standard reference
photographs taken during slit lamp examination. The extent of
opaciﬁcation of cortical (C) and posterior subcapsular (P) changes
was deﬁned, and color changes of the nucleus as well as the
intensity of nuclear opalescence was noted using LOCS. Lens
opacity was scored according to the description in LOCS, for
example, N0 and NIV were denoted as 0 and 4, respectively. After
adding the scores of the 4 parts (nuclear color, nuclear opacity,
cortical cataracts, and posterior subcapsule), a total score (0–15)
was obtained. These scores were used to categorize cataracts into
5 stages: score 0, Stage 1; scores 1 to 4, Stage 2; scores 5 to 8,
Stage 3; scores 9 to 12, Stage 4; and scores 13 to 15, Stage 5.Two-dimensional Gel Electrophoresis
Sample Preparation and Running of Gels
An aliquot containing 100 mg of protein sample was diluted
with 350 mL of rehydration buffer containing 8-M urea, 4% [3-
(3-cholamidopropyl)dimethylammonio]-1- propanesulfonate],
65-mM dithioerythritol (DTE), 0.5% ampholytes, and a trace of
bromophenol blue. An immobilized pH gradient (17 cm; pH 3–10;
ReadyStrip IPG strip; Bio-Rad, Tokyo, Japan) was hydrated
overnight, and the samples were focused for a total of 60 kVh
(PROTEAN IEF cell; Bio-Rad) at 201C and then stored at 801C.
Strips were equilibrated with 3 mL of an equilibrium solution
containing 50-mM Tris–hydrocholride (pH 8.8), 6-M urea, 30%glycerol, 2% sodium dodecyl sulfate (SDS), a trace of bromophenol
blue, and DTE (1% w/v) for 20 minutes, followed by equilibration
for 20 minutes in the same solution containing iodoacetamide
(IAA; 2.5% w/v) instead of DTE. The strips were transferred to the
tops of 12% PAGE and held in position with molten 0.5% agarose in
running buffer containing 25-mM Tris, 0.192-M glycine, and 0.1%
SDS. The gels were run at 16 mA for 30 minutes, followed by 50
mA for 4 to 5 hours.
Detection of Protein Spots and Data Analysis
The gels were routinely stained with Coomassie blue and then
scanned using a GS-800 imaging densitometer with PDQuest
software (version 7.1.1; Bio-Rad). To evaluate intra- and inter-
sample variability, the gels were analyzed as follows: protein
spots from each gel were detected and matched automatically to
generate a master gel image from the matched gel sets. Finally,
the intensity of the spots was compared between gels. Data
were exported to Microsoft Excel (Microsoft Inc, Redmond,
Washington) for creating correction and spot intensity graphs.
In-Gel Digestion
The procedure of Terry et al18 was slightly modiﬁed and used
for in-gel digestion of proteins from the Coomassie blue-stained
gels for nanoscale capillary LC/MS/MS. In brief, each spot of
interest on the Coomassie blue-stained gel was sliced into
1-mm cubes. The proteins in these gels were reduced and
methylated with 50-mM DTE and 100-mM IAA in 50-mM ammo-
nium bicarbonate. The gel pieces were washed 2 times with 50%
v/v acetonitrile (ACN) in 100-mM ammonium bicarbonate buffer
(pH 8.0) for 10 minutes at room temperature. They were then
soaked in 100% ACN for 5 minutes, dried in a lyophilizer for 20 to
30 minutes, and rehydrated in 50-mM ammonium bicarbonate
buffer (pH 8.0) containing 10 mg/mL trypsin (Promega, Madison,
Wisconsin) until fully immersed. After incubating for 16 to 20
hours at 301C, the remaining trypsin solution was transferred into
a new microtube. The gel pieces were resuspended with 50% ACN
in 5.0% formic acid (FA) for 60 minutes, and then concentrated to
dryness.Nanoelectrospray Mass Spectrometry
Nanoscale capillary LC/MS/MS was used to analyze the pro-
teins involved in the development of cataracts. The Ultimate
Capillary LC System (LC Packings, Amsterdam, the Netherlands)
coupled to a QSTARXL quadrupole-time of ﬂight (Q-TOF) mass
spectrometer (Applied Biosystem/MDS Sciex, Foster City, Califor-
nia) was used for analysis. Nanoscale capillary LC separation was
performed on a reverse phase C18 column (15 cm  75 mm inner
diameter) with a ﬂow rate of 200 nL/min and a 60-minute linear
gradient of 5% to 50% buffer B. Buffer A contained 0.1% FA in 5%
aqueous ACN, and buffer B contained 0.1% FA in 95% aqueous
ACN. The nano-LC tip for online LC/MS was a PicoTip (FS360-20-
10-D-20; New Objective, Cambridge, Massachusetts). Data acqui-
sition was performed using automatic information dependent
acquisition (IDA; Applied Biosystem/MDS Sciex). Automatic IDA
ﬁnds the most intense ions in TOF MS spectra and then performs
optimized MS/MS analysis on these ions. The product ion spectra
generated by nano-LC/MS/MS were searched against National
Center for Biotechnology Information (NCBI) databases for exact
matches using the ProID program (Applied Biosystem/MDS Sciex)
and the MASCOT search program (MASCOT search program;
Matrix Science, Inc, Boston, Massachusetts). A mammalian tax-
onomy restriction was used, and the mass tolerance of both
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Figure 1. Spots 1 to 44 existed in Stage 2 cataracts. MW, molecular weight.
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Figure 3. Spots 92 to 129 existed in Stage 4 cataracts. MW, molecular weight.
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methyl cysteine was set as a ﬁxed modiﬁcation, whereas phos-
phorylation of serine, threonine, and tyrosine, and other
modiﬁcations were set as variable modiﬁcations. All identiﬁed
phosphopeptides were conﬁrmed by manual interpretation of the
spectra.Results
Lens materials from various stages were prepared for
2D-PAGE. To identify protein expression, master gels were com-
puted from scanned images of quartet silver-stained gels. The
scanned gel images were processed using the Proteomics Soft-
ware System developed by Xzillion (Frankfurt am Main,
Germany). The master gel was computed by registering and
jointly segmenting multiple registered replicates. Algorithmic
details can be found in the SEQUEST algorithm (version C1;
Thermo Fisher Scientiﬁc, Waltham, Massachusetts) incorporated200.0
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Figure 2. Spots 45 to 91 existed in Stage 3 cataracts. MW, molecular weight.into the ThermoFinnigan BIOWORKS software (version 3.0;
Thermo Fisher Scientiﬁc). Spot volumes were determined by
modeling optical density of individual spot segments using 2D
Gaussian analysis. To correct for variability due to gel electro-
phoresis, quartet gels were run for each cataract stage. In addi-
tion, spots expressed in o50% of the gels were disregarded.
Furthermore, upregulation of proteins was considered signiﬁcant
when the corresponding spot volumes were increased by more
than twofold. Representative master gels showed proteins
expressed in different stages of cataracts. The proteins varied
between 10 and 120 kDa in size and had isoelectric point (pI)
values ranging from 5 to 9 (Figures 1–4).
No patient with Stage 1 cataracts underwent surgery; therefore,
data were collected from patients with Stage 2 to 5 cataracts. Spots
1 to 44 were expressed in Stage 2 (Figure 1 and Tables I and II).
After analysis, the major proteins in Stage 2 were crystallin bB1,
aB, a A, and bA4. Eleven spots were identiﬁed as crystallin bB1. Of
these, 5 were phosphorylated, 1 was acetylated, and none was
truncated. In addition, 11 protein spots were identiﬁed as200.0
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Figure 4. Spots 130 to 175 existed in Stage 5 cataracts. MW, molecular weight.
Table I
Proteins identiﬁed from mass spectrometry.
Spot
No.
Accession
No.
Protein Identiﬁcation MW
(kDa) /pI
Score Post-
translational
Modiﬁcation
1 P02489 a-Crystallin A chain 19.9/5.77 448 Ac Pi
2 P02489 a-Crystallin A chain 19.9/5.77 464 Ac Pi
3 P02489 a-Crystallin A chain 19.9/5.77 511 Ac Pi
4 P02489 a-Crystallin A chain 19.9/5.77 375 Pi
5 P02489 a-Crystallin A chain 19.9/5.77 561 Ac Pi
6 P02489 a-Crystallin A chain 19.9/5.77 642 Ac Pi
7 P02489 a-Crystallin A chain 19.9/5.77 383 Pi
8 P02489 a-Crystallin A chain 19.9/5.77 365 Ac
9 P53673 b-Crystallin A4 22.2/5.82 526 Pi
10 P53673 b-Crystallin A4 22.2/5.82 407 Pi
11 P53673 b-Crystallin A4 22.2/5.82 510
12 P53673 b-Crystallin A4 22.2/5.82 546 Pi
13 P02489 a-Crystallin A chain 19.9/5.77 475
14 P53673 b-Crystallin A4 22.2/5.82 413
15 P53674 b-Crystallin B1 27.9/8.59 1068 Pi
16 P05813 b-Crystallin A3 25.1/5.81 665 Ac Pi
17 P53673 b-Crystallin A4 22.2/5.82 541
18 P07320 g-Crystallin D 20.6/7.15 519
19 P53674 b-Crystallin B1 27.9/8.59 1077 Ac Pi
20 P53674 b-Crystallin B1 27.9/8.59 928
21 P53674 b-Crystallin B1 27.9/8.59 1177 Pi
22 P53674 b-Crystallin B1 27.9/8.59 1145
23 P53674 b-Crystallin B1 27.9/8.59 1073
24 P53674 b-Crystallin B1 27.9/8.59 1215 Pi
25 P53674 b-Crystallin B1 27.9/8.59 1135 Pi
26 P53674 b-Crystallin B1 27.9/8.59 1081 Pi
27 P53674 b-Crystallin B1 27.9/8.59 932
28 P53674 b-Crystallin B1 27.9/8.59 926
29 P43320 b-Crystallin B2 23.2/6.54 679
30 P07315 g-Crystallin C 20.7/7.04 650
31 P07320 g-Crystallin D 20.6/7.15 450
32 P07315 g-Crystallin C 20.7/7.04 665
33 P02511 a-Crystallin B chain 20.1/6.76 515
34 P02511 a-Crystallin B chain 20.1/6.76 607 Pi
35 P02511 a-Crystallin B chain 20.1/6.76 591 Pi
36 P02511 a-Crystallin B chain 20.1/6.76 694 Pi
37 P02511 a-Crystallin B chain 20.1/6.76 565
38 P02511 a-Crystallin B chain 20.1/6.76 407
39 P02511 a-Crystallin B chain 20.1/6.76 338
40 P02489 a-Crystallin A chain 19.9/5.77 409 Ac
41 Q01469 Fatty acid-binding
protein
15.0/6.84 207
42 P02489 a-Crystallin A chain 19.9/5.77 441
43 P02489 a-Crystallin A chain 19.9/5.77 309
44 P02489 a-Crystallin A chain 19.9/5.77 402
45 P02489 a-Crystallin A chain 19.9/5.77 354 Ac Pi
46 P02489 a-Crystallin A chain 19.9/5.77 481 Ac Pi
47 P02489 a-Crystallin A chain 19.9/5.77 557 Ac Pi
48 P02489 a-Crystallin A chain 19.9/5.77 661 Ac Pi
49 P22914 b-Crystallin S 20.9/6.43 515 Ac Pi
50 P53674 b-Crystallin B1 27.9/8.59 586
51 P02489 a-Crystallin A chain 19.9/5.77 597 Ac Pi
52 P02489 a-Crystallin A chain 19.9/5.77 564 Ac Pi
53 P05813 b-Crystallin A3 25.1/5.81 569 Pi
54 P05813 b-Crystallin A3 25.1/5.81 708 Ac Pi
55 P53674 b-Crystallin B1 27.9/8.59 1105 Ac Pi
56 P05813 b-Crystallin A3 25.1/5.81 753 Pi
57 P53674 b-Crystallin B1 27.9/8.59 1051 Ac Pi
58 P05813 b-Crystallin A3 25.1/5.81 688 Pi
59 P05813 b-Crystallin A3 25.1/5.81 847 Pi
60 P02511 a-Crystallin B chain 20.1/6.76 595 Pi
61 P43320 b-Crystallin B2 23.2/6.54 437 Ac Pi
62 P53674 b-Crystallin B1 27.9/8.59 1033 Pi
63 P53674 b-Crystallin B1 27.9/8.59 637
64 P53674 b-Crystallin B1 27.9/8.59 1022 Pi
65 P53674 b-Crystallin B1 27.9/8.59 1082 Pi
66 P43320 b-Crystallin B2 23.2/6.54 703
67 P05813 b-Crystallin A3 25.1/5.81 640
68 P53674 b-Crystallin B1 27.9/8.59 1058 Pi
69 P53674 b-Crystallin B1 27.9/8.59 1366 Pi
70 P02511 a-Crystallin B chain 20.1/6.76 791
71 P02511 a-Crystallin B chain 20.1/6.76 497
Table I (continued)
Spot
No.
Accession
No.
Protein Identiﬁcation MW
(kDa) /pI
Score Post-
translational
Modiﬁcation
72 P02511 a-Crystallin B chain 20.1/6.76 510
73 P02511 a-Crystallin B chain 20.1/6.76 466 Pi
74 P05813 b-Crystallin A3 25.1/5.81 427
75 P07320 g-Crystallin D 20.6/7.15 216
76 P02511 a-Crystallin B chain 20.1/6.76 239
77 P02489 a-Crystallin A chain 19.9/5.77 373
78 P53673 b-Crystallin A4 22.2/5.82 484
79 P02489 a-Crystallin A chain 19.9/5.77 511 Ac Pi
80 P53673 b-Crystallin A4 22.2/5.82 442
81 P53673 b-Crystallin A4 22.2/5.82 523
82 P53673 b-Crystallin A4 22.2/5.82 478
83 P53673 b-Crystallin A4 22.2/5.82 436
84 P53673 b-Crystallin A4 22.2/5.82 362
86 P02489 a-Crystallin A chain 19.9/5.77 364 Ac
87 P02489 a-Crystallin A chain 19.9/5.77 309
88 P02489 a-Crystallin A chain 19.9/5.77 278
89 P02489 a-Crystallin A chain 19.9/5.77 201
90 P02489 a-Crystallin A chain 19.9/5.77 234
91 P02489 a-Crystallin A chain 19.9/5.77 247
92 P02489 a-Crystallin A chain 19.9/5.77 135
93 P53674 b-Crystallin B1 27.9/8.59 155
94 P53674 b-Crystallin B1 27.9/8.59 432
95 P53674 b-Crystallin B1 27.9/8.59 718
96 P53674 b-Crystallin B1 27.9/8.59 337
97 P53674 b-Crystallin B1 27.9/8.59 945
98 P53674 b-Crystallin B1 27.9/8.59 889
99 P53674 b-Crystallin B1 27.9/8.59 1009
100 P05813 b-Crystallin A3 25.1/5.81 691
101 P05813 b-Crystallin A3 25.1/5.81 551 Ac Pi
102 P53674 b-Crystallin B1 27.9/8.59 1071 Pi
103 P53674 b-Crystallin B1 27.9/8.59 1029
104 P05813 b-Crystallin A3 25.1/5.81 608
105 P53674 b-Crystallin B1 27.9/8.59 1214 Pi
106 P05813 b-Crystallin A3 25.1/5.81 621
107 P53674 b-Crystallin B1 27.9/8.59 786
108 P53674 b-Crystallin B1 27.9/8.59 997 Pi
109 P53674 b-Crystallin B1 27.9/8.59 923
110 P53674 b-Crystallin B1 27.9/8.59 1161 Pi
111 P53674 b-Crystallin B1 27.9/8.59 927
112 P53674 b-Crystallin B1 27.9/8.59 876
113 P05813 b-Crystallin A3 25.1/5.81 551
114 P05813 b-Crystallin A3 25.1/5.81 475
115 P07315 g-Crystallin C 20.7/7.04 465
116 P02511 a-Crystallin B chain 20.1/6.76 170
117 P02511 a-Crystallin B chain 20.1/6.76 239
118 P02489 a-Crystallin A chain 19.9/5.77 206
119 P53673 b-Crystallin A4 22.2/5.82 192
120 P53673 b-Crystallin A4 22.2/5.82 447
121 P53673 b-Crystallin A4 22.2/5.82 539
122 P02489 a-Crystallin A chain 19.9/5.77 296
123 P53673 b-Crystallin A4 22.2/5.82 424
124 P53673 b-Crystallin A4 22.2/5.82 475
125 P53673 b-Crystallin A4 22.2/5.82 481
126 P53673 b-Crystallin A4 22.2/5.82 444
127 P53673 b-Crystallin A4 22.2/5.82 512
128 P53673 b-Crystallin A4 22.2/5.82 396
129 P02489 a-Crystallin A chain 19.9/5.77 485
130 P53673 b-Crystallin A4 22.2/5.82 402
131 P02489 a-Crystallin A chain 19.9/5.77 513 Ac Pi
132 P02489 a-Crystallin A chain 19.9/5.77 494 Ac Pi
133 P02489 a-Crystallin A chain 19.9/5.77 641 Ac Pi
134 P02489 a-Crystallin A chain 19.9/5.77 707 Ac Pi
135 P02489 a-Crystallin A chain 19.9/5.77 506 Ac Pi
136 P53673 b-Crystallin A4 22.2/5.82 517
137 P53673 b-Crystallin A4 22.2/5.82 570
138 P02489 a-Crystallin A chain 19.9/5.77 579 Ac Pi
139 P53673 b-Crystallin A4 22.2/5.82 553 Pi
140 P02489 a-Crystallin A chain 19.9/5.77 460 Ac Pi
141 P02489 a-Crystallin A chain 19.9/5.77 409 Ac Pi
142 P02489 a-Crystallin A chain 19.9/5.77 329
143 P02489 a-Crystallin A chain 19.9/5.77 553
144 P02489 a-Crystallin A chain 19.9/5.77 755 Ac Pi
145 P02489 a-Crystallin A chain 19.9/5.77 641 Pi
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Spot
No.
Accession
No.
Protein Identiﬁcation MW
(kDa) /pI
Score Post-
translational
Modiﬁcation
146 P53673 b-Crystallin A4 22.2/5.82 372
147 P02489 a-Crystallin A chain 19.9/5.77 308
149 P53673 b-Crystallin A4 22.2/5.82 405
150 P02489 a-Crystallin A chain 19.9/5.77 439 Pi
151 P07320 g-Crystallin D 20.6/7.15 458
152 P02511 a-Crystallin B chain 20.1/6.76 775 PiAc
153 P07320 g-Crystallin D 20.6/7.15 445
154 P02511 a-Crystallin B chain 20.1/6.76 882 Pi
155 P02511 a-Crystallin B chain 20.1/6.76 948 PiAc
156 P43320 b-Crystallin B2 23.2/6.54 1292 Ac
157 P43320 b-Crystallin B2 23.2/6.54 1346 PiAc
158 P02511 a-Crystallin B chain 20.1/6.76 693
159 P02511 a-Crystallin B chain 20.1/6.76 489
160 P02511 a-Crystallin B chain 20.1/6.76 895 PiAc
161 P02511 a-Crystallin B chain 20.1/6.76 982 PiAc
162 P02511 a-Crystallin B chain 20.1/6.76 964 Pi
163 P02511 a-Crystallin B chain 20.1/6.76 268
164 P02511 a-Crystallin B chain 20.1/6.76 228 Pi
166 P02511 a-Crystallin B chain 20.1/6.76 758
167 P02511 a-Crystallin B chain 20.1/6.76 821 Pi
169 P02511 a-Crystallin B chain 20.1/6.76 282
170 P02511 a-Crystallin B chain 20.1/6.76 307
171 P02489 a-Crystallin A chain 19.9/5.77 314
172 P02489 a-Crystallin A chain 19.9/5.77 255 Ac
173 P02489 a-Crystallin A chain 19.9/5.77 284
175 P02489 a-Crystallin A chain 19.9/5.77 143
Ac, acetylation; MW, molecular weight; Pi, phosphorylation; PiAc, phosphoryla-
tion, acetylation; pI, isoelectric point.
H.-J. Lin et al. / Current Therapeutic Research 74 (2013) 9–15 13crystallin aB in Stage 2. Of these, 5 were phosphorylated, 1 was
both phosphorylated and acetylated, and none was truncated.
Eleven spots were identiﬁed as crystallin aA. Six of these were
phosphorylated, 6 were acetylated, 5 were both phosphorylated
and acetylated, and all were truncated. Eight spots were identiﬁed
as crystallin bA4. Of these, 3 were phosphorylated and none was
acetylated. However, all crystallin bA4 proteins were truncated.
Among the protein spots in Stage 2, 46.3% were phosphorylated
(Tables I and II); the ratio of phosphorylated to nonphosphorylated
proteins was 17:24 (41.46% phosphorylated proteins). Acetylated
proteins were more abundant than nonacetylated ones; the ratio
of acetylated to nonacetylated proteins was 8:33. Only 19.5% of
crystallin proteins in Stage 2 were acetylated. The ratio of
truncated to nontruncated proteins was 19:22 (46.3% truncated)
(Tables I and II). The proportions of phosphorylated and truncated
proteins were high in Stage 2, whereas that of acetylated proteins
was low.
The major proteins associated with Stage 3 (Figure 2 and Tables
I and II) were crystallin aA, bB1, bA3, and bA4. Thirteen proteins
were identiﬁed as crystallin aA, 6 of which were phosphorylated,
7 were acetylated, and 5 were both phosphorylated and acetylated.
All crystallin aA proteins in Stage 3 were truncated. Ten proteins
were identiﬁed as crystallin bB1. Of these, 8 were phosphorylated,
2 were acetylated, and none was truncated. Six proteins were
identiﬁed as crystallin bA3. Of these, 5 were phosphorylated, 1 was
acetylated, and all 6 were truncated. Six proteins in Stage 3 were
identiﬁed as crystallin bA4. None of these were phosphorylated or
acetylated; however, they were all truncated. In Stage 3, the ratio
of phosphorylated to nonphosphorylated proteins was 19:16
(54.2% phosphorylated). The ratio of acetylation was lower than
that of phosphorylation, with 10:25 (28.6%) proteins carrying
acetyl groups (Tables I and II). The ratio of truncated to nontrun-
cated proteins was 25:10, indicating that more than half of the
proteins in Stage 3 were truncated (71.4%; Tables I and II). The
phosphorylation ratio in Stage 3 was higher than that in Stage 2(Stage 3 to Stage 2, 54.3%:46.3%). Similarly, the acetylation ratio in
Stage 3 was also higher than that in Stage 2 (Stage 3 to Stage 2,
28.6%:19.5%). In contrast, the truncation ratio was increased in
Stage 3 (Stage 3 to Stage 2, 71.4%:46.3%) (Tables I and II).
The major lens proteins associated with Stage 4 were crystallin
bB1 and bA4 (Figure 3 and Table II). Sixteen proteins were
identiﬁed as crystallin bB1. Of these, 4 were phosphorylated,
and none was acetylated or truncated. In addition, 9 proteins
were identiﬁed as crystallin bA4, none of which was modiﬁed or
truncated. The ratio of phosphorylated to nonphosphorylated
proteins in Stage 4 was 4:21. The prevalence of modiﬁcations
such as phosphorylation (16%), acetylation (0%), and truncation
(0%) decreased in Stage 4 (Tables I and II).
The major protein components associated with Stage 5 cataract
lenses (Figure 4 and Tables I and II) were crystallin aA, bA4, and
aB. Of these, 19 proteins were identiﬁed as truncated crystallin
aA, and 11 of them were phosphorylated. Fourteen proteins were
identiﬁed as crystallin aB. Of these, 8 were phosphorylated,
4 were acetylated, and none was truncated. Six proteins were
identiﬁed as crystallin bA4, 1 of which was phosphorylated, and
none was acetylated or truncated. In Stage 5, the ratio of
phosphorylated to nonphosphorylated proteins was 20:19, that
of acetylated to nonacetylated proteins was 4:35, and that of
truncated to nontruncated proteins was 19:20. The prevalence of
phosphorylation (51.3%) and truncation (48.7%) increased again in
Stage 5, whereas that of acetylated crystallin proteins (10.3%)
remained low (Table II).Discussion
Cataract and intraocular lens surgery is progressing at an
astonishing speed.19,20 Nevertheless, cataracts are still the leading
cause of blindness worldwide,4,5,13 especially in underdeveloped
countries where cataract surgery is not widely available.15 Where
it is available, cataract surgery continues to be expensive, repre-
senting a signiﬁcant cost to health services in many nations.21 The
etiology of cataracts involves induction of free radicals and
superoxide-mediated damage to lens proteins by ultraviolet
(UV) light.22,23 The mechanisms of this disease remain elusive,
and preventative medicines have not yet been discovered.20 In
this study, we used proteomic analyses to determine differential
expression and post-translational modiﬁcations of lens proteins
during the development of cataracts.
Crystallins were identiﬁed as the most differentially expressed
proteins in cataract lenses. The pI of human lens proteins was
distributed from 5 to 9, and the molecular weight was between 10
and 120 kDa. Phosphorylation and truncation were increased in
the early stages of lens clouding, indicating that these modiﬁca-
tions of crystallins might contribute to the formation of catar-
acts.24–27 Acetylation of crystallins was not as marked as
phosphorylation in the opaque lens, although acetylation
increased with the progression of cataracts. In contrast, phos-
phorylation, truncation, and acetylation decreased in Stage 4. This
might indicate that the modiﬁcation of crystallin proteins is not
important in maintaining lens opacity in late-stage cataracts. In
addition, microscopic structures of lenses begin to deteriorate in
Stage 4; however, modiﬁcation and truncation of crystallin
proteins were not predominant in this stage. The major compo-
nents of human lens crystallin were aA, bB1, aB, and bA4. The
abundance of crystallin bA4 did not change with the progression
of cataracts, and it remained the major component in every stage.
Crystallin bB1 was also a dominant component in Stages 2 to
4 human cataract lenses; however, it disappeared in Stage
5 cataracts. These data suggested that crystallin bB1 is important
in the progression of lens opacity in early and middle stages.
Table II
The proteins expressed in cataracts.
Stage Total Protein Number Proteins (no.) Phosphorylation (%) Acetylation (%) Truncation (%)
2 44 bB1 11 aB 11 aA 11 bA4 8 Others 3 19 (46.3) 8 (19.5) 19 (46.3)
3 47 aA 13 bB1 10 bA3 6 bA4 6 Others 12 19 (54.3) 10 (28.6) 25 (71.4)
4 38 bB1 16 bA4 9 Others 13 4 (16) 0 0
5 46 aA 19 bA4 14 aB 6 Others 7 20 (51.3) 4 (10.3) 19 (48.7)
H.-J. Lin et al. / Current Therapeutic Research 74 (2013) 9–1514Nevertheless, in severely opaque lenses, such as those in Stage 5,
the basic structure had deteriorated to that of severe cataracts,
such as morgagnian cataracts, and crystallin bB1 was totally
absent. Crystallin aA was predominantly expressed in Stages 2,
3, and 5; however, it was not present in Stage 4. Therefore,
crystallin aA might be involved in very early stages of cataract
formation and later stages of severely opaque lenses. Very similar
aB expression was noted in Stages 2 and 5.28–32
N-acetylcarnosine or carcinine eye drops resistant to enzy-
matic hydrolysis could act as pharmacological chaperones and
decrease oxidative stress and excessive glycation in stress-
related eyes such as cataracts. Ischemic diabetic retinopathy
might protect against nuclear sclerotic cataracts, and these ﬁnd-
ings were consistent with the hypothesis that increased
exposure to oxygen is responsible for nuclear cataract forma-
tion.33 None of the patients in this study used these drugs
regularly, but the relations of these drugs’ antioxidative function
and the crystalline changes noted in this study are worthy of
advanced studies.34 In contrast, 2 well-known drugs, corticoster-
oids35 and the antipsychotic drug quetiapine,36 can induce catar-
acts; none of our patients received these drugs for 41 month;
therefore, they were not the issues of our study. Cataracts are also
classiﬁed by their location, with the posterior type usually due to
steroid and diabetes mellitus.35,37 To decrease the special cataract
type–induced bias in the study, the score of LOCS classiﬁcation
focus in any part, and the difference of any 2 parts over 4
(denoted as 0 and 4 by the 2 parts), were excluded from this
study. To study the crystalline expression of different cataracts is
also an important issue and worthy of study in the future. Other
special type cataracts, such as traumatic cataracts, congenital
cataracts, and exfoliation syndrome, were excluded in this study
to obtain the simple information of natural progressing cataracts.
In conclusion, crystallin protein levels and post-translational
modiﬁcations were changeable during the progression of
cataracts.Conclusions
Crystallin protein levels and post-translational modiﬁcations
were changeable during the progression of cataracts. Understand-
ing these protein dynamics during the formation of cataracts
might help in designing distinct treatments for this disease.Acknowledgments
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